Patients with terminal forms of leukemia and lymphoma who have run out of treatment options could soon benefit from a new drug, which not only puts an end to chemotherapy and has virtually no side effects.
The phosphatidylinositol-3-kinase delta inhibitor idelalisib shows antitumor activity in patients with indolent non-Hodgkin lymphoma and chronic lymphocytic leukemia.
The use of radioimmunotherapy treatment in patients with newly diagnosed follicular lymphoma has been investigated in a new study.
Specialized fat molecules, called sphingolipids, play a key role in the survival of aggressive lymphomas caused by viruses, according to new research.
Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|